GX
LRMR icon

Greylock XII’s Larimar Therapeutics LRMR Stock Holding History

Greylock XII’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,847
Closed -$441K – 2
2015
Q4 		$441K Buy
+5,847
New +$939K 2.04% 2

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Greylock XII's LRMR Position: Q1 2016 in Review

Greylock XII sold out of Larimar Therapeutics (LRMR) in Q1 2016, closing a stake of 5,847 shares — an estimated $441K sold.

Greylock XII first reported a position in LRMR in Q4 2015 and held it in 1 quarter. The position peaked at $441K in Q4 2015. 80 funds tracked by Wall St. Rank hold LRMR as of Q1 2016.

  • Greylock XII reported no remaining Larimar Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Greylock XII sold 5,847 Larimar Therapeutics shares in Q1 2016, an estimated $441K.
  • Greylock XII first reported a position in Larimar Therapeutics in Q4 2015 and held it in 1 quarter.
  • Greylock XII's Larimar Therapeutics position peaked at $441K in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2016.

Based on Greylock XII's 13F filing for Q1 2016, filed 22 Apr 2016.